When developing a novel medical product, endpoint selection is arguably one of the most important decisions a sponsor will make. In the rapidly evolving sector of digital and hardware-based interventions, this choice becomes even more critical. Sponsors face a complex set of challenges: proving genuine clinical relevance, supporting a robust regulatory or claims strategy, selecting realistic targets, and generating evidence that is credible across the board – for clinicians, regulators, payers and commercial teams.
Metabolic health devices represent a broad and innovative category. These can include glucose monitoring tools, connected body composition devices, digital therapeutics, remote monitoring platforms, wearables, lifestyle-support devices, and software-based tools. Because the technology is so varied, a one-size-fits-all approach to metabolic health clinical study design simply does not work. Partnering with a specialized medical device CRO for metabolic health is often the most effective way to navigate these waters and build an evidence package that holds up under scrutiny.
Table of Contents
Why Endpoint Selection Matters in Metabolic Health Device Studies
Endpoints Must Match the Intended Use of the Device
A device designed to monitor, guide, predict, support behavior change, or definitively measure metabolic status will need vastly different endpoint strategies. A continuous glucose monitor requires a completely different clinical approach than a digital therapeutic app designed to encourage weight loss. Matching the endpoints to the exact intended use is the foundation of any successful metabolic health clinical study design.
Weak Endpoint Choices Can Limit Regulatory and Commercial Value
Endpoints that are too broad, insensitive to change, or poorly aligned with the product’s core claim can severely weaken the evidence package. If a sponsor intends to claim that a device improves glycemic control but only measures user engagement, regulatory bodies will reject the claim. Commercial teams and payers similarly demand hard data; weak clinical endpoints for metabolic devices translate directly to limited market access and diminished commercial value.
Metabolic Health Outcomes Are Influenced by Many Confounders
Human metabolism is complex and highly reactive. Outcomes are heavily influenced by a myriad of confounders: diet, physical activity, sleep patterns, concomitant medication use, baseline metabolic status, adherence to the intervention, seasonality, and overall lifestyle variation. Without measuring or controlling for these factors, it becomes impossible to isolate the true effect of the device. An experienced medical device CRO for metabolic health will build these controls into the protocol to ensure data integrity.
What Counts as a Metabolic Health Device?
Digital Health and Software-Based Devices
This category includes software as a medical device (SaMD) tools, digital therapeutics (DTx), metabolic coaching apps, and algorithm-based risk or behavior platforms. These tools often aim to change user behavior or provide clinical decision support based on user inputs.
Wearables and Remote Monitoring Devices
Physical hardware worn by the user falls into this group. Examples include activity trackers, connected scales, continuous or intermittent monitoring tools and advanced sleep and activity sensors. Building robust clinical evidence for metabolic health wearables is critical as these devices shift from consumer wellness to clinical-grade utility.
Glucose and Biomarker Monitoring Devices
These are the foundational tools for metabolic tracking. Examples encompass CGM-related tools, traditional blood glucose monitors, novel metabolic biomarker tracking tools and connected testing systems.
Weight, Body Composition, and Lifestyle Support Devices
Examples include connected scales, bioelectrical impedance analysis (BIA) devices, appetite or nutrition-support tools, and hardware explicitly designed to support weight management journeys.
Start With the Claim: What Is the Device Trying to Prove?
Monitoring Claims
For devices that simply track or measure metabolic markers without making therapeutic claims, endpoints must focus on the device’s technical capabilities. Primary endpoints may focus on measurement accuracy, reliability, data completeness, user compliance, and usability.
Behavior Change Claims
For devices designed to actively influence lifestyle, the endpoints need to reflect human action. Appropriate endpoints may include protocol adherence, changes in physical activity, dietary behavior shifts, sleep improvements, weight change, and patient-reported outcomes (PROs).
Clinical Improvement Claims
If a device claims a measurable, physiological metabolic benefit, the endpoints must be solid clinical markers. For these dynamic claims, metabolic health device clinical trial endpoints could include HbA1c, fasting glucose, body weight, waist circumference, blood pressure, lipid markers, insulin resistance metrics, Heart Rate Variability (HRV) or validated quality-of-life measures.
Risk Prediction or Decision-Support Claims
For algorithm-driven platforms that interpret data to predict outcomes or guide clinician choices, the focus shifts to data science metrics. Endpoints may include sensitivity, specificity, predictive performance, agreement with established reference methods, and clinical usability in a real-world setting.
Regulatory and Evidence Considerations for Metabolic Health Device
EU MDR Clinical Evaluation Considerations
Under the EU Medical Device Regulation (MDR), clinical evidence must rigorously support safety, performance, and clinical benefits depending strictly on the device’s intended purpose. The European Commission’s Medical Device Coordination Group (MDCG) guidance provides essential, up-to-date guidance documents for applying MDR and In Vitro Diagnostic Regulation (IVDR) requirements. These cover vital areas related to clinical evaluation, software classification, and clinical investigations.
FDA Expectations for Digital and Remote Data Collection
For devices utilizing apps, wearables, or remote monitoring frameworks, the FDA has established clear expectations. Recent FDA guidance covers the use of digital health technologies (DHTs) to acquire data remotely in clinical investigations, noting explicitly that these tools can include both hardware and software. Sponsors must prove that remote data capture is as reliable as in-clinic assessments.
Patient-Centered and Fit-for-Purpose Outcome Measures
Where patient-reported outcomes or functional measures are deployed, endpoint selection must be undeniably fit-for-purpose. The FDA’s 2025 final guidance on clinical outcome assessments describes exactly how patient experience data, alongside other relevant patient or caregiver information, can effectively support medical product development and eventual regulatory decision-making.
Why Early Endpoint Alignment Helps Avoid Study Redesign
A failure to align early is a costly mistake in metabolic health clinical trials. It is imperative to align clinical, regulatory, statistical, and operational teams before finalizing the protocol. Engaging a medical device CRO for metabolic health during the drafting phase ensures that the primary endpoints satisfy regulators, while secondary endpoints provide the narrative the commercial team needs, preventing expensive mid-study protocol amendments.
Primary, Secondary, Exploratory, and Safety Endpoints: How Sponsors Should Think About the Hierarchy
When determining how to choose endpoints for metabolic health device trials, understanding the endpoint hierarchy is non-negotiable.
Primary Endpoints
Primary endpoints should directly support the main study objective and validate the most important device claim. This is the metric upon which the study’s statistical power is based. It must be highly relevant, scientifically valid, and practically measurable.
Secondary Endpoints
Secondary endpoints add crucial clinical depth. They show consistency across various physiological systems and support broader product positioning. For instance, if the primary endpoint is weight loss, a secondary endpoint might be improved blood pressure.
Exploratory Endpoints
Exploratory endpoints are useful for biomarker discovery, future claim development, uncovering subgroup insights, or planning next-phase studies. These help sponsors to gather data on novel markers without risking the primary statistical analysis plan of their metabolic health clinical trials.
Safety and Tolerability Endpoints
These are paramount for all device types, especially those that actively influence user behavior, nutrition, glucose management, or clinical decision-making. Safety is always the first hurdle any medical product must clear.
Core Endpoint Categories for Metabolic Health Device Studies
Glycemic Endpoints
These metrics evaluate how effectively the body manages blood sugar. Key endpoints include:
- HbA1c
- Fasting blood glucose
- Postprandial glucose (PPG)
- Continuous glucose monitoring metrics
- Time in range (TIR)
- Glucose variability
- Hypoglycemic or hyperglycemic events
Glycemic endpoints are most relevant when the device is explicitly linked to glucose monitoring, diabetes management, insulin resistance, or metabolic risk reduction.
Weight and Anthropometric Endpoints
These measure physical changes in the body’s mass and shape. Key endpoints include:
- Body weight
- Body Mass Index (BMI)
- Waist circumference
- Waist-to-hip ratio
- Body fat percentage
- Visceral fat estimates
- Lean mass or skeletal muscle mass
Weight alone may not be enough for some devices, especially where the product aims to improve body composition, lower localized metabolic risk (like visceral adiposity), or foster sustainable lifestyle behaviors rather than rapid, transient weight loss.
Metabolic Biomarker Endpoints
Understanding what endpoints sponsors should consider in metabolic health device studies often requires looking beneath the surface at physiological biomarkers. Included in metabolic biomarkers clinical trials are:
- Fasting insulin
- HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
- Lipid profile
- Triglycerides
- HDL and LDL cholesterol
- Blood pressure
- hs-CRP (High-Sensitivity C-Reactive Protein) or other inflammatory markers
- Liver enzymes
- Ketones
- Appetite or satiety biomarkers (e.g., leptin, ghrelin)
Behavioral and Lifestyle Endpoints
Because metabolic health is intrinsically tied to daily habits, measuring behavior is vital:
- Physical activity
- Step count
- Exercise minutes
- Sleep duration and sleep quality
- Dietary adherence
- Calorie or macronutrient tracking
- App engagement
- Coaching session completion
- Device usage frequency
Patient-Reported Outcomes and Quality-of-Life Measures
The user’s subjective experience can define a device’s long-term viability:
- Energy levels
- Hunger and satiety
- Cravings
- Sleep quality
- Perceived control over health
- Treatment burden
- Diabetes distress
- Weight-related quality of life
- Usability and satisfaction
PROs should be selected carefully and must measure something genuinely meaningful to the end-user, not just something convenient for the sponsor to track.
Device Performance and Usability Endpoints
If the device doesn’t work reliably, the clinical data is moot:
- Measurement accuracy
- Precision and repeatability
- Agreement with reference methods (e.g., comparing a wearable sensor to lab-drawn blood)
- Data completeness
- Missing data rates
- App or dashboard usability
- User error rates
- Device adherence
- Technical failure rates
- Algorithm performance
Safety Endpoints
Protecting participants is the ultimate priority:
- Adverse events (AEs)
- Device-related adverse events
- Skin irritation or wearability issues (common with wearables and patches)
- Hypoglycemia risk
- Incorrect readings or false alerts
- Over-reliance on device outputs
- Behavioral risks, such as excessive dietary restriction or inappropriate changes in activity levels
How Atlantia Supports Metabolic Health Device Studies
Endpoint Strategy and Protocol Design
Atlantia aligns endpoints directly to sponsor’s corporate objectives, device claims, and practical study feasibility. We know exactly how to choose endpoints for metabolic health device trials to maximize regulatory success.
Clinical Operations Across EU and USA Sites
With robust, wholly owned clinical infrastructure in Cork, Ireland, and Chicago, USA, Atlantia provides a unified, transatlantic approach to execution as a leading medical device CRO for metabolic health.
Recruitment of Relevant Metabolic Health Populations
Finding the right participants is critical. Atlantia excels in recruiting healthy adults, overweight/obese participants, metabolically at-risk groups, and condition-specific patients where appropriate for metabolic health clinical trials.
Biomarker, Anthropometric, and Digital Endpoint Collection
Atlantia is highly capable of integrating complex clinical data, biomarker assays, device outputs, and participant-reported data into a single, cohesive database, streamlining metabolic biomarkers in clinical trials.
Hybrid and Remote Study Delivery
We understand the need for modern trial designs. Our capabilities in hybrid and decentralized study delivery connect seamlessly to digital health device studies, wearables and longitudinal metabolic monitoring protocols.
Data Quality, Compliance, and Sponsor-Ready Reporting
As an expert medical device CRO for metabolic health, Atlantia emphasizes clean, compliant evidence packages, high endpoint interpretability, and operational reliability.
Conclusion: Strong Endpoint Strategy Builds Stronger Evidence
Executing metabolic health clinical trials requires a careful, deliberate balance of clinical relevance, flawless device performance, positive participant experience, and rigorous operational feasibility. Determining exactly what endpoints sponsors should consider in metabolic health device studies is the first, most important step in that journey. Without a precise endpoint strategy, even the most innovative technology will struggle to find regulatory approval or market adoption.
Planning a metabolic health device study? Atlantia Clinical Trials supports sponsors with endpoint strategy, protocol design, recruitment, clinical operations, biomarker collection, and EU/USA study delivery. Partner with a dedicated medical device CRO for metabolic health to ensure your next trial delivers the evidence you need.
Frequently Asked Questions
Are digital endpoints useful in metabolic health device studies?
Yes, highly useful. Generating robust clinical evidence for metabolic health wearables and digital therapeutics relies heavily on digital endpoints like step counts, continuous heart rate variability, app engagement, and digitally captured sleep architecture. These act as vital clinical endpoints for metabolic devices aiming to influence behavior.
Can metabolic health device studies be run remotely or using a hybrid model?
Absolutely. Many metabolic health clinical trials utilize hybrid or fully decentralized models. Because devices like wearables and CGM systems continuously capture data in real-world settings, an experienced medical device CRO for metabolic health can leverage this technology to reduce site visits and enhance patient retention through an optimized metabolic health clinical study design.